wobei besonders die letzten Abschnitte zu beachten sind:
DrugAnalyst Partners the independent equity research firm comment upon the
recent deal between Roche Holdings AG and Antisoma.
Roche will buy 10% of Antisoma's stock for £4.15m and pays $37m upfront. In
return the Swiss company acquires the rights to all oncology drugs developed
by Antisoma over the next 5 years. Roche will make additional payments based
upon drug development successes that could, if all developments were
successful, be as much as $500m over the coming years. Antisoma shares soared,
more than doubling, in delight at the deal.
With a $500m headline price tag, no wonder Antisoma shares have jumped,
however, it is worth asking who has got the best deal here, and what does it
mean for the Antisoma shareprice?
Roche gets Antisoma's key drug Pemtumomab, a tratment for ovarian cancer,
after Antisoma agreed to cancel a previous deal with Abbott in order to sign
this agreement with Roche. With an upfront price tag of $37m this is a good
deal for Roche, however, for Antisoma...
If Pemtumomab proves successful, and there are many hurdles yet to leap, then
Antisoma has done this deal too cheaply. On the other hand, if the drug fails,
Roche may still point to options on future products, but Antisoma is as dead
in the water as it would have ever been. It is not the deals that make you
rich but the successful drugs you develop.
We think Antisoma sold out too early and too cheaply. Nice deal for Roche but
little reason to think Antisoma is going to be any more successful today than
it was yesterday.
We are taking our Antisoma profits and running.
Automatically generated by the Bloomberg Research Publisher, Version 3.2
So viel zu diesem Thema, Du bist wieder dran ;-))
hartmoneygruesse
